Roche (RHHBY) To Buy Adheron Therapeutics For $580M

Roche has a strong presence in the oncology market backed by products like Herceptin, Perjeta and Kadcyla. The Adheron acquisition is a step toward Roche’s efforts to develop its portfolio beyond oncology to immunology.